Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Berlin, DE · Author affiliation
*Department of Neurology, St Joseph Hospital Berlin-Weißensee, Berlin; and †Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany; and ‡Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Schlieren; §Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich; and ∥Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.Location evidence
Würzburg, DE · Author affiliation
*Department of Neurology, St Joseph Hospital Berlin-Weißensee, Berlin; and †Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany; and ‡Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Schlieren; §Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich; and ∥Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.Location evidence
Zürich, CH · Author affiliation
*Department of Neurology, St Joseph Hospital Berlin-Weißensee, Berlin; and †Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany; and ‡Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Schlieren; §Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich; and ∥Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BackgroundBiogenic amines and monoamine oxidase inhibitors influence peripheral monoamine oxidase enzyme activity in chronic levodopa/dopa decarboxylase inhibitor–treated patients with Parkinson disease. Rasagiline is an irreversible inhibitor of monoamine oxidase B. Safinamide blocks this isoenzyme in a reversible fashion.ObjectivesThe aim of this study was to determine monoamine oxidase A (plasma) and B (platelets) enzyme activity in long-term levodopa-treated patients without and with additional oral intake of 50- or 100-mg safinamide or 1-mg rasagiline or first-time intake of rasagiline.ResultsMonoamine oxidase A enzyme activity did not differ between all groups. Patients on rasagiline or safinamide showed lower monoamine oxidase–B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. No impact of the number of previous oral levodopa intakes was found.DiscussionRasagiline and safinamide did not essentially differ in terms of inhibition of monoamine oxidase B despite their different pharmacology regarding reversibility of monoamine oxidase B inhibition. In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.